SRR23303776
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- Male
GSVA pathway preview (0 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-ZF-A9R5-01A-12R-A42T-07 | — | — | 0.833 |
| 2 | SAMN03290916 | — | — | 0.833 |
| 3 | SRR23303775 | — | — | 0.776 |
| 4 | SRR650134 | — | — | 0.773 |
| 5 | SRR2755094 | — | — | 0.772 |
| 6 | SAMN03290914 | — | — | 0.770 |
| 7 | SRR1313108 | — | B | 0.770 |
| 8 | MBCProject_4647_T0_RNA | — | B | 0.766 |
| 9 | sclc283559_S82.txt | — | cohortSC | 0.762 |
| 10 | SRR4195665 | — | — | 0.756 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 5 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.360 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.180 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.140 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.110 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.030 | Inavolisib | — uncovered |